Disease · MONDO_0009807

osteosarcoma

6 sourcesdiseases-2026-09-18-0.1.0

Cite this record

ConductScience Library. osteosarcoma. Diseases, record MONDO_0009807. Release diseases-2026-09-18-0.1.0, 18 Sept 2026. https://conductscience.org/library/diseases/MONDO_0009807

On this page

Disease

Names and IDs as Open Targets gives them. Its IDs in MeSH, Orphanet, the Disease Ontology and the NCI Thesaurus are those Open Targets states for it.

Name: osteosarcoma; Open Targets
Open Targets ID: MONDO_0009807; Open Targets
Other names: OS, osteogenic sarcoma, osteoid sarcoma, osteosarcoma (disease), osteosarcoma, malignant, sarcoma of osteoid; Open Targets
Disease Ontology: DOID:3347; Disease Ontology
MeSH: D012516; MeSH
NCI Thesaurus: C9145; NCI Thesaurus
Highest stage of its drugs: Approval, for 4 of its 141 drugs, from DailyMed and EMA Human Drugs; Open Targets

Drugs141

The drugs Open Targets' clinical reports study for the disease, the highest stage first, then the most trial reports. The stage is Open Targets', the highest any of its sources reports for the pair, and each row names the sources that report it.

Drug	ChEMBL ID	Type	Open Targets' stage	Stage reported by	Reports	Of them trials	Trials shown here	Source
LEUCOVORIN CALCIUM	CHEMBL1201138	Small molecule	Approval	DailyMed	9	8	8	Drugs and targets
MIFAMURTIDE	CHEMBL2107354	Small molecule	Approval	EMA Human Drugs	7	6	6	Drugs and targets
LEVOLEUCOVORIN	CHEMBL1908841	Small molecule	Approval	DailyMed	2	0	0	Drugs and targets
LEVOLEUCOVORIN CALCIUM	CHEMBL1908361	Small molecule	Approval	DailyMed	1	0	0	Drugs and targets
IFOSFAMIDE	CHEMBL1024	Small molecule	Phase 3	ClinicalTrials.gov	30	30	30	Drugs and targets
METHOTREXATE	CHEMBL34259	Small molecule	Phase 3	ClinicalTrials.gov	29	29	29	Drugs and targets
CISPLATIN	CHEMBL11359	Small molecule	Phase 3	ClinicalTrials.gov	28	27	27	Drugs and targets
DOXORUBICIN	CHEMBL53463	Small molecule	Phase 3	ClinicalTrials.gov	19	19	18	Drugs and targets
ETOPOSIDE	CHEMBL44657	Small molecule	Phase 3	ClinicalTrials.gov	16	16	16	Drugs and targets
CYCLOPHOSPHAMIDE	CHEMBL1200796	Small molecule	Phase 3	ClinicalTrials.gov	15	15	15	Drugs and targets

1 to 10 of 141

See all 141 drugs

Targets185

The targets ChEMBL's mechanism records give for the disease's drugs, through Open Targets, the most drugs first. A mechanism record says what a drug acts on, not that the target causes the disease.

Target	Protein	Its drugs that act on it	Mechanisms	Highest stage of those drugs	Gene in Genes	Source
KDR	Vascular endothelial growth factor receptor	14	Vascular endothelial growth factor receptor 2 inhibitor; Vascular endothelial growth factor receptor inhibitor	Phase 2/3	https://conductscience.org/library/genes/3791	Drugs and targets
FLT4	Vascular endothelial growth factor receptor	10	Vascular endothelial growth factor receptor 3 inhibitor; Vascular endothelial growth factor receptor inhibitor	Phase 2	https://conductscience.org/library/genes/2324	Drugs and targets
FLT1	Vascular endothelial growth factor receptor	9	Vascular endothelial growth factor receptor 1 inhibitor; Vascular endothelial growth factor receptor inhibitor	Phase 2	https://conductscience.org/library/genes/2321	Drugs and targets
KIT	Mast/stem cell growth factor receptor Kit	8	Stem cell growth factor receptor inhibitor	Phase 2	https://conductscience.org/library/genes/3815	Drugs and targets
PDGFRB	Platelet-derived growth factor receptor	8	Platelet-derived growth factor receptor beta inhibitor; Platelet-derived growth factor receptor inhibitor	Phase 2	https://conductscience.org/library/genes/5159	Drugs and targets
TUBA1A	Tubulin	8	Tubulin inhibitor	Phase 3	https://conductscience.org/library/genes/7846	Drugs and targets
TUBA1B	Tubulin	8	Tubulin inhibitor	Phase 3	https://conductscience.org/library/genes/10376	Drugs and targets
TUBA1C	Tubulin	8	Tubulin inhibitor	Phase 3	https://conductscience.org/library/genes/84790	Drugs and targets
TUBA3C	Tubulin	8	Tubulin inhibitor	Phase 3	https://conductscience.org/library/genes/7278	Drugs and targets
TUBA3E	Tubulin	8	Tubulin inhibitor	Phase 3	https://conductscience.org/library/genes/112714	Drugs and targets

1 to 10 of 185

See all 185 targets

Trials172

Trials an Open Targets clinical report links to the disease, posted results first, then the largest. A trial is shown when the release's checks confirm its link to the disease and Drugs and targets shows its link to one of the disease's drugs. 4 more are not shown, since the checks do not confirm them.

Trial	Title	Phase	Participants	Results first posted	Conditions	Drugs	Linked by	Source
NCT00134030	Combination Chemotherapy, PEG-Interferon Alfa-2b, and Surgery in Treating Patients With Osteosarcoma	Phase 3	1,334	2023-06-07	Localized Osteosarcoma, Metastatic Osteosarcoma	CISPLATIN, DOXORUBICIN HYDROCHLORIDE, ETOPOSIDE, IFOSFAMIDE, METHOTREXATE, PEGINTERFERON ALFA-2B	Its record names the disease	ClinicalTrials.gov
NCT00642941	A Study of R1507 in Participants With Recurrent or Refractory Sarcoma	Phase 2	317	2021-02-03	Sarcoma	TEPROTUMUMAB	Its record names the disease	ClinicalTrials.gov
NCT00617890	A Study to Determine the Activity of Robatumumab (SCH 717454) in Participants With Relapsed Osteosarcoma or Ewing's Sarcoma (MK-7454-002/P04720)	Phase 2	219	2015-12-11	Osteosarcoma, Sarcoma, Ewing's, Peripheral Neuroectodermal Tumor	ROBATUMUMAB	Its record names the disease	ClinicalTrials.gov
NCT02357810	Pazopanib Hydrochloride and Topotecan Hydrochloride in Treating Patients With Metastatic Soft Tissue and Bone Sarcomas	Phase 2	178	2020-08-10	Adult Liposarcoma, Metastatic Liposarcoma, Metastatic Osteosarcoma, Recurrent Adult Soft Tissue Sarcoma, Recurrent Liposarcoma, Recurrent Osteosarcoma, Stage IV Adult Soft Tissue Sarcoma	PAZOPANIB HYDROCHLORIDE, TOPOTECAN HYDROCHLORIDE	Its record names the disease	ClinicalTrials.gov
NCT02304458	Nivolumab With or Without Ipilimumab in Treating Younger Patients With Recurrent or Refractory Solid Tumors or Sarcomas	Phase 1/2	140	2023-01-10	Metastatic Melanoma, Recurrent Ewing Sarcoma/Peripheral Primitive Neuroectodermal Tumor, Recurrent Hodgkin Lymphoma, Recurrent Malignant Solid Neoplasm, Recurrent Melanoma, Recurrent Neuroblastoma, Recurrent Non-Hodgkin Lymphoma, Recurrent Osteosarcoma, Recurrent Rhabdomyosarcoma, Refractory Ewing Sarcoma/Peripheral Primitive Neuroectodermal Tumor, Refractory Hodgkin Lymphoma, Refractory Malignant Solid Neoplasm, Refractory Melanoma, Refractory Neuroblastoma, Refractory Non-Hodgkin Lymphoma, Refractory Osteosarcoma, Refractory Rhabdomyosarcoma, Stage III Cutaneous Melanoma AJCC v7, Stage IIIA Cutaneous Melanoma AJCC v7, Stage IIIB Cutaneous Melanoma AJCC v7, Stage IIIC Cutaneous Melanoma AJCC v7, Stage IV Cutaneous Melanoma AJCC v6 and v7, Unresectable Melanoma	IPILIMUMAB, NIVOLUMAB	Its record names the disease	ClinicalTrials.gov
NCT02879162	Durvalumab and Tremelimumab in Patients With Advanced Rare Tumours	Phase 2	140	2025-02-17	Advanced Rare Tumours	DURVALUMAB, TREMELIMUMAB	Its record names the disease	ClinicalTrials.gov
NCT00560235	Study Of CP-751,871 In Patients With Ewing's Sarcoma Family Of Tumors	Phase 1/2	138	2014-02-28	Ewing's Sarcoma Family of Tumors	FIGITUMUMAB	Its record names the disease	ClinicalTrials.gov
NCT02048371	SARC024: A Blanket Protocol to Study Oral Regorafenib in Patients With Selected Sarcoma Subtypes	Phase 2	131	2023-11-07	Liposarcoma, Osteogenic Sarcoma, Ewing/Ewing-like Sarcoma, Rhabdomyosarcoma, Mesenchymal Chondrosarcoma	REGORAFENIB	Its record names the disease	ClinicalTrials.gov
NCT02406781	Combination of MK3475 and Metronomic Cyclophosphamide in Patients With Advanced Sarcomas : Multicentre Phase II Trial	Phase 2	129	2025-12-10	Sarcoma	CYCLOPHOSPHAMIDE, PEMBROLIZUMAB	Its record names the disease	ClinicalTrials.gov
NCT01154816	Alisertib in Treating Young Patients With Recurrent or Refractory Solid Tumors or Leukemia	Phase 2	118	2017-06-05	Hepatoblastoma, Previously Treated Childhood Rhabdomyosarcoma, Recurrent Childhood Acute Lymphoblastic Leukemia, Recurrent Childhood Acute Myeloid Leukemia, Recurrent Childhood Kidney Neoplasm, Recurrent Childhood Malignant Germ Cell Tumor, Recurrent Childhood Rhabdomyosarcoma, Recurrent Childhood Soft Tissue Sarcoma, Recurrent Ewing Sarcoma/Peripheral Primitive Neuroectodermal Tumor, Recurrent Neuroblastoma, Recurrent Osteosarcoma	ALISERTIB	Its record names the disease	ClinicalTrials.gov

1 to 10 of 172

See all 172 trials

Comparisons in its trials20

Comparisons Trial comparisons calculated in the trials shown here, most participants first. A comparison in one of these trials does not always compare a treatment for the disease, so read the two groups.

Comparison	Group 1, with the outcome	Group 2, with the outcome	Participants	Trial	Source
Osteosarcoma vs Ewing Sarcoma: Incidence of Adverse Events	45 of 45	45 of 45	90	NCT02243605	Trial comparisons
Osteosarcoma vs Ewing Sarcoma: deaths from any cause	42 of 45	37 of 45	90	NCT02243605	Trial comparisons
Osteosarcoma vs Ewing Sarcoma: serious adverse events	30 of 45	31 of 45	90	NCT02243605	Trial comparisons
Cohort 1: Measurable vs Cohort 2: Resection: deaths from any cause	13 of 15	20 of 38	53	NCT02470091	Trial comparisons
Cohort 1: Measurable vs Cohort 2: Resection: serious adverse events	6 of 15	4 of 38	53	NCT02470091	Trial comparisons
Group 1 (Unilateral Recurrence) vs Group 2 (Bilateral Recurrence): serious adverse events	4 of 27	0 of 16	43	NCT00066365	Trial comparisons
A: Localized Resectable Disease vs C: Metastatic Tumors: serious adverse events	3 of 31	0 of 11	42	NCT00667342	Trial comparisons
Cohort A: Liposarcoma Crossover vs Cohort B: Osteosarcoma Crossover: Response Rate (RR), Cohorts A and B, After Crossover.	0 of 15	0 of 11	26	NCT02048371	Trial comparisons
Cisplatin Liposomal 24 mg/m2 vs Cisplatin Liposomal 36 mg/m2: deaths from any cause	0 of 7	0 of 12	19	NCT00102531	Trial comparisons
Cisplatin Liposomal 24 mg/m2 vs Cisplatin Liposomal 36 mg/m2: serious adverse events	1 of 7	2 of 12	19	NCT00102531	Trial comparisons

1 to 10 of 20

See all 20 comparisons in its trials

Papers from its trials75

The papers the trials shown here list on ClinicalTrials.gov as their results (RESULT) or as drawn from them (DERIVED), results first, newest first.

PMID	Listed as	Trials listing it	Source
39737219	RESULT	1	PubMed
36303228	RESULT	1	PubMed
35618839	RESULT	1	PubMed
32547189	RESULT	1	PubMed
32376724	RESULT	1	PubMed
32192573	RESULT	2	PubMed
31595663	RESULT	1	PubMed
31553693	RESULT	1	PubMed
31447583	RESULT	1	PubMed
31013172	RESULT	2	PubMed

1 to 10 of 75

See all 75 papers from its trials

Data dates

The date of each source this release read.

Open Targets: 2026-09-18; Open Targets
Drug links and their checks, from Drugs and targets: 2026-09-18; Drugs and targets
ClinicalTrials.gov, from Trials: 2026-11-12; Trials
Comparisons, from Trial comparisons: 2026-03-23; Trial comparisons
PubMed, for the checks: 2026-11-06; PubMed
MeSH, for the checks: 2026-11-10; MeSH

Sources 6

ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
ChEMBL, through Open TargetsCC BY-SA 3.0
ClinicalTrials.govNo license stated
NLM's MeSHNLM's terms
Open TargetsCC0 1.0
PubMedNLM's terms

Each source's terms

ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
ClinicalTrials.govnone stated
NLM's MeSHNLM's
Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
PubMedNLM's terms

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this disease from software.

The record and each of its lists are JSON, twenty rows a page. No key.

GET https://conductscience.org/api/diseases/v1/MONDO_0009807

GET https://conductscience.org/api/diseases/v1/MONDO_0009807/drugs?page=2

API reference For AI assistants